Literature DB >> 8965119

New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis.

R Arnon1, M Sela, D Teitelbaum.   

Abstract

Copolymer 1 is a synthetic amino acid copolymer, effective in suppression of experimental allergic encephalomyelitis (EAE) induced in a variety of species. Copolymer 1 can suppress both acute and chronic relapsing EAE induced by either whole brain homogenate or the purified encephalitogens myelin basic protein (MBP) and proteolipid protein (PLP). Thus, the suppressive effect of copolymer 1 in EAE is a general phenomenon and is not restricted to a certain species, the disease type, or the encephalitogen used for EAE induction. The suppressive activity of copolymer 1 is, however, limited to EAE, and copolymer 1 has no nonspecific immunological activity. On the other hand, a marked degree of immunological cross-reactivity in both the cellular and humoral immune responses was demonstrated between MBP and copolymer 1. This cross-reactivity may be the underlying mechanism for the specific suppressive effect of copolymer 1 in EAE. In vivo and in vitro studies using both murine and human cell cultures suggest that the mechanism for copolymer 1 activity in EAE and multiple sclerosis involves, as an initial step, the binding of copolymer 1 to the major histocompatibility complex class II molecules on antigen-presenting cells. Following this step, two pathways may be activated: (1) induction of antigen-specific suppressor T cells by determinants shared between MBP and copolymer 1, or (2) competition with MBP and other myelin-associated antigens, PLP and myelin oligodendrocyte glycoprotein, for the activation of effector T cells. These two mechanisms can act either separately or in concert to interfere in the autoimmune processes that lead to the neurological damage in EAE and multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8965119     DOI: 10.1007/bf00873696

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  24 in total

1.  Chronic relapsing experimental allergic encephalomyelitis: an experimental model of multiple sclerosis.

Authors:  H M Wiśniewski; A B Keith
Journal:  Ann Neurol       Date:  1977-02       Impact factor: 10.422

2.  Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen.

Authors:  D Teitelbaum; C Webb; A Meshorer; R Arnon; M Sela
Journal:  Eur J Immunol       Date:  1973-05       Impact factor: 5.532

3.  Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide.

Authors:  D Teitelbaum; A Meshorer; T Hirshfeld; R Arnon; M Sela
Journal:  Eur J Immunol       Date:  1971-08       Impact factor: 5.532

Review 4.  Experimental allergic encephalomyelitis--susceptibility and suppression.

Authors:  R Arnon
Journal:  Immunol Rev       Date:  1981       Impact factor: 12.988

Review 5.  Immunospecific drug design--prospects for treatment of autoimmune diseases.

Authors:  R Arnon; D Teitelbaum
Journal:  Ther Immunol       Date:  1994-01

6.  Suppression of experimental allergic encephalomyelitis in Rhesus monkeys by a synthetic basic copolymer.

Authors:  D Teitelbaum; C Webb; M Bree; A Meshorer; R Arnon; M Sela
Journal:  Clin Immunol Immunopathol       Date:  1974-11

7.  Molecular requirements involved in suppression of EAE by synthetic basic copolymers of amino acids.

Authors:  C Webb; D Teitelbaum; A Herz; R Arnon; M Sela
Journal:  Immunochemistry       Date:  1976-04

8.  Synthetic copolymer 1 and myelin basic protein do not require processing prior to binding to class II major histocompatibility complex molecules on living antigen-presenting cells.

Authors:  M Fridkis-Hareli; D Teitelbaum; R Arnon; M Sela
Journal:  Cell Immunol       Date:  1995-07       Impact factor: 4.868

9.  Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein.

Authors:  D Teitelbaum; R Milo; R Arnon; M Sela
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

10.  T suppressor hybridomas and interleukin-2-dependent lines induced by copolymer 1 or by spinal cord homogenate down-regulate experimental allergic encephalomyelitis.

Authors:  R Aharoni; D Teitelbaum; R Arnon
Journal:  Eur J Immunol       Date:  1993-01       Impact factor: 5.532

View more
  7 in total

Review 1.  Therapeutic strategies in multiple sclerosis. I. Immunotherapy.

Authors:  R Hohlfeld
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-10-29       Impact factor: 6.237

2.  Risk-benefit assessment of glatiramer acetate in multiple sclerosis.

Authors:  T Ziemssen; O Neuhaus; R Hohlfeld
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

3.  Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis.

Authors:  R Aharoni; D Teitelbaum; M Sela; R Arnon
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

4.  Ameliorative effect of PN-277 on laser-induced retinal damage.

Authors:  Shiri Shulman; Mark Belokopytov; Galina Dubinsky; Michael Belkin; Mordechai Rosner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-11-06       Impact factor: 3.117

5.  Multiple Sclerosis: Immunotherapy.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-07       Impact factor: 3.972

6.  Divergent Immunomodulation Capacity of Individual Myelin Peptides-Components of Liposomal Therapeutic against Multiple Sclerosis.

Authors:  Vilena V Ivanova; Svetlana F Khaiboullina; Marina O Gomzikova; Ekaterina V Martynova; André M Ferreira; Ekaterina E Garanina; Damir I Sakhapov; Yakov A Lomakin; Timur I Khaibullin; Evgenii V Granatov; Farit A Khabirov; Albert A Rizvanov; Alexander Gabibov; Alexey Belogurov
Journal:  Front Immunol       Date:  2017-10-16       Impact factor: 7.561

Review 7.  Immunological Aspects of Approved MS Therapeutics.

Authors:  Paulus S Rommer; Ron Milo; May H Han; Sammita Satyanarayan; Johann Sellner; Larissa Hauer; Zsolt Illes; Clemens Warnke; Sarah Laurent; Martin S Weber; Yinan Zhang; Olaf Stuve
Journal:  Front Immunol       Date:  2019-07-11       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.